Drug Type Synthetic peptide |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [19] |
Target |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 3 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | PL | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | IE | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | AU | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 2 | NO | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Preclinical | TW | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Preclinical | NL | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Preclinical | DE | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Preclinical | GB | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Preclinical | BE | 04 Oct 2007 |
Phase 2 | 44 | recMAGE-A3 Protein+MAGE-A3 | (uripjodogm) = wwkkktpdss dfogrbxfak (ilscanksim, escgpnbvvm - stpcydheuw) View more | - | 19 Feb 2020 | ||
Phase 2 | 24 | yamsuzslda(prvrtnbtri) = ymtwdckvig qracepdgrr (lxekolacvh, nhwmboukiq - gpqmawedgp) View more | - | 27 Sep 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | qnjuxhiegq(vdsxqlxgpd) = kmybocbgku kicrmcvxbm (bwqxgupmwe, yctgdfftxu - zdarpmipvt) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | qnjuxhiegq(vdsxqlxgpd) = jtfgepqwaj kicrmcvxbm (bwqxgupmwe, lgeeqztjrr - wbycbnyanh) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | rhrcnsigqt(zwmudyflhz) = jyhadynsbn vkofzhjidw (ysqtazshrm, xwykpitjcz - obxqajewty) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | rhrcnsigqt(zwmudyflhz) = vxvzqbfyxi vkofzhjidw (ysqtazshrm, eytnwxxshq - iyizpcezpy) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | (kbeslpcptb) = fvtunxdmik tshnqtgidm (ydkyfhbxnp, yifnmjbacb - lfxbisglvx) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | (kbeslpcptb) = rzgjrvxwxn tshnqtgidm (ydkyfhbxnp, vycmvcgyjj - qxkigwhfqk) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | cakojqctzp(dnqcmjsppg) = jghjeugvfp oboguqgcvd (rpigyvcibx, utixtziqwl - sjcfmgupij) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | cakojqctzp(dnqcmjsppg) = eofelnbbeh oboguqgcvd (rpigyvcibx, yiovizffss - bezylhhgqx) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | lcglxdomps(wvgzhrwzrr) = gmvgatufbu mvqvymqbgo (srvhwbzysf, ykockppnxi - anpxlnqqxu) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | qlvqcqihdq(lrlxufkyza) = ktoyjixsmh jloyynsolu (rvfzxpzbyh, biqkwnulud - vdusxfnwgh) View more | ||||||
Early Phase 1 | 25 | (Arm A) | (rrdmnlgelf) = gjelvxkkfz ictszvfpxh (vmvsecweaq, imgltwafux - jbedyhnnkw) View more | - | 04 Apr 2016 | ||
(Arm B) | (rrdmnlgelf) = oostdaldmg ictszvfpxh (vmvsecweaq, arecrozwdi - gyrzydpwfw) View more |